Please assess the completion status of the following clinical trial:

Trial Title: Erector Spinae Block for Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adults aged greater than or equal to 18 years old and less than or equal to 85 years old.~* Patients who are scheduled to undergo lumbar spinal surgery (1-2 level) and willing and able to provide informed consent.~Exclusion criteria:~* Patients with a history of chronic opioid use for \> 3 months including but not limited to fentanyl, morphine, oxycodone, methadone.~* Patients with known allergy or intolerance to any drug used in the study including local anesthetics and total intravenous anesthesia medications.~* Patients with a history of alcohol or drug abuse.~* Patients with a history of intolerance of nonsteroidal anti-inflammatory drugs.-Patients with hepatic insufficiency.~* Patients with renal insufficiency.~* Patients who are pregnant.~* Patients with American Society of Anesthesiologists physical status of 4 or greater.~* Patients on immunosuppressive therapy. Pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine only (Type: ACTIVE_COMPARATOR): bupivacaine 0.25% in ESP blocks
- Liposomal Bupivacaine and Bupivacaine (Type: EXPERIMENTAL): liposomal bupivacaine in addition to 0.25% bupivacaine in ESP blocks

Based on this trial design, predict the completion outcome and termination type (if applicable).